The FDA has rejected a biologics license application for apitegromab to treat spinal muscular atrophy, according to manufacturer Scholar Rock.

Why you should embrace it in your workforce by Robert D. Austin and Gary P. Pisano Meet John. He’s a wizard at data analytics. His combination of mathematical ability and software development skill is ...